DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

REDEFINE 1 trial results

Adults with obesity or overweight with a related condition, without diabetes.

CagriSemaWegovy injection
Phase
Phase 3a
Follow-up
68 weeks
Randomised
3,417
Sponsor
Novo Nordisk
Publication
New England Journal of Medicine · 2025

Double-blind, active- and placebo-controlled. Treatment-policy estimand.

Mean body weight change at 68 weeks
  • CagriSema 2.4 mg / 2.4 mg−20.4%
  • Semaglutide 2.4 mg−14.9%
  • Cagrilintide 2.4 mg−11.5%
  • Placebo−3.0%
Mean body weight change at 68 weeks
Trial armResult
CagriSema 2.4 mg / 2.4 mg−20.4%
Semaglutide 2.4 mg−14.9%
Cagrilintide 2.4 mg−11.5%
Placebo−3.0%

Safety. Gastrointestinal events were the most frequently reported adverse events with CagriSema.